SCHEMBL730974

SCHEMBL730974

CCOc1cc(C(=O)OC)cc(OCC)c1-c1cnoc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.42
CREBBP Q92793 2/20 0.40
TSHR P16473 5/20 0.39
MAPK1 P28482 2/20 0.39
GAA P10253 1/20 0.39
KDM4E B2RXH2 3/20 0.38
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.36
CNR2 P34972 1/20 0.36
MAPT P10636 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ATAD2 Q6PL18 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
GLA P06280 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15178386 0.93 CNR2 (0.47) S1PR1CREBBPTSHRMAPK1GAA
SCHEMBL732774 0.86 TSHR (0.44) CREBBPTSHRGAAKDM4EKMT2A
SCHEMBL733580 0.77 ROCK2 (0.46) S1PR1CREBBP
SCHEMBL1501791 0.75 S1PR1 (0.51) S1PR1CREBBPTSHRKDM4EALDH1A1
SCHEMBL731379 0.75 PDK2 (0.45) S1PR1CREBBPTSHR
SCHEMBL730899 0.73 AAK1 (0.44) TSHRMAPK1KMT2ACNR2L3MBTL1
SCHEMBL28030473 0.72 TSHR (0.66) TSHRGAAKMT2AMEN1GLA
SCHEMBL29633582 0.72 KDM4E (0.51) CREBBPTSHRMAPK1GAAKDM4E
SCHEMBL1501800 0.72 S1PR1 (0.50) S1PR1CREBBPTSHRGAAKMT2A
SCHEMBL1501518 0.71 TSHR (0.56) CREBBPTSHRMAPK1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 S1PR1 1461/4885CREBBP 3128/4885TSHR 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.